BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Khurana S, Kahl A, Yu K, DuPont AW. Recent advances in the treatment of Clostridioides difficile infection: the ever-changing guidelines. Fac Rev 2020;9:13. [PMID: 33659945 DOI: 10.12703/b/9-13] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Inose R, Muraki Y, Kamimoto Y, Kusama Y, Koizumi R, Yamasaki D, Ishikane M, Tanabe M, Ohmagari N. The intended purpose and regional patterns of use of antibiotics for managing Clostridioides (Clostridium) difficile infections: An analysis of the National Database of Health Insurance Claims and Specific Health Checkups data of Japan. J Infect Chemother 2021:S1341-321X(21)00340-8. [PMID: 34916136 DOI: 10.1016/j.jiac.2021.12.004] [Reference Citation Analysis]
2 Rahmoun LA, Azrad M, Peretz A. Antibiotic Resistance and Biofilm Production Capacity in Clostridioides difficile. Front Cell Infect Microbiol 2021;11:683464. [PMID: 34422678 DOI: 10.3389/fcimb.2021.683464] [Reference Citation Analysis]
3 Gotshal D, Azrad M, Hamo Z, Nitzan O, Peretz A. IL-16 and BCA-1 Serum Levels Are Associated with Disease Severity of C. difficile Infection. Pathogens 2021;10:631. [PMID: 34065379 DOI: 10.3390/pathogens10050631] [Reference Citation Analysis]